jetcityimage
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the economic effects of the company’s popular weight loss therapy, tirzepatide, branded as Zepbound.
Writing for the U.K.’s The Telegraph newspaper, Secretary of State